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Dual diagnosis with substance use disorders (SUDs)
consistently contributes to the premature mortality
and increased disability observed in schizophrenia.
Large genome-wide association studies are providing
the information needed to investigate the genetic
architecture of psychiatric disorders. Here, we discuss
recent genetic investigations of dual diagnosis
(i.e., schizophrenia plus a SUD) and how these findings
can inform public health messages.genesis of dual diagnosis in schizophrenia.Theories of dual diagnosis
The comorbidity between a mental illness and a substance
use disorder (SUD; i.e., a condition in which the use of
one or more substances leads to a clinically relevant
impairment or to distress) is usually defined as a dual
diagnosis. This is frequent, dangerous and problematic
when the psychiatric illness is schizophrenia (in this
article, we will refer to comorbidity specifically of
schizophrenia and a SUD as “dual diagnosis”). Individuals
with schizophrenia are more likely than those without the
disorder to smoke, heavily use alcohol, heavily use canna-
bis, and use recreational drugs; these factors contribute to
the premature mortality and increased disability observed
in patients with schizophrenia [1]. Accordingly, under-
standing the pathogenesis of dual diagnosis as an entity
has the potential to improve clinical outcomes. There are
four major theories to explain the prevalence of dual
diagnosis. First, the “self-medication” hypothesis suggests
that individuals with schizophrenia develop a SUD
because they feel it improves some of their symptoms. A
second possibility is that schizophrenia and SUDs are
influenced by a common pathophysiology (i.e., shared
genetic mechanisms). Third, in the diathesis-stress model,
genetic predisposition interacts with chronic substance* Correspondence: renato.polimanti@yale.edu
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schizophrenia. A final theory is that impaired social and
occupational function due to schizophrenia together with
exposure to poor social environments coincide with an
increased risk of substance use. Numerous approaches
have been used to investigate these hypotheses, but sub-
stantive progress in understanding the underlying genetic
architecture has been made only recently. Here, we
describe the results from genome-wide association studies
(GWAS) and discuss how this information can be used to
test the above-mentioned hypotheses regarding the patho-Genetic overlap between schizophrenia and SUDs
Early family studies provided mixed evidence regarding the
co-aggregation of SUDs in the relatives of schizophrenic
probands. GWAS are now contributing greatly to our
understanding of the genetic predisposition to complex
traits. GWAS test the association of common variation
across the entire human genome, and can therefore gener-
ate new hypotheses or provide unbiased information to
support or refute old ones. For instance, GWAS of sub-
stance dependencies showed evidence of local genetic over-
lap and identified risk genes that had previously been
associated with schizophrenia risk [2]. In 2014, the
Schizophrenia Working Group of the Psychiatric Genomics
Consortium published a meta-analysis of GWAS that
included up to 36,989 cases and 113,075 controls, and
identified 108 novel genetic loci associated with the risk of
schizophrenia [3]. Data from this study boosted research in
schizophrenia genetics more generally, providing investiga-
tors with the resources needed to study pleiotropy and to
conduct post-GWAS analyses. Summary statistics from this
GWAS were used to perform polygenic risk score (PRS)
analyses to investigate the global genetic overlap between
schizophrenia and many other traits, including SUDs. For
instance, addressing the uncertain association between can-
nabis use and schizophrenia, the overall genetic correlation
with summary statistics from a recent large meta-analysis
of cannabis use (rg) is 0.22 [4, 5], which supports thele is distributed under the terms of the Creative Commons Attribution 4.0
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these two traits. A PRS study from deCODE Genetics
conducted on 144,609 Icelandic subjects tested the associ-
ation of schizophrenia PRSs with several SUD-related traits;
the authors observed significant associations for disorders
of alcohol, amphetamine, cocaine, cannabis, opioid and
sedative use, as well as an early onset of addiction, smoking
initiation, Fagerström Test for Nicotine Dependence,
number of cigarettes smoked per day, and the number of
hospital admissions for in-patient addiction treatment
(Nagelkerke’s R2 0.08 to 0.89%) [6]. Collectively, these re-
sults indicate that shared covariance from common genetic
variation is implicated in the comorbidity of schizophrenia
and SUDs. However, on the basis of these genetic correla-
tions alone, no conclusions can be drawn regarding the
mechanisms that link these complex traits.
Causal relationships
Mendelian randomization (MR) methods offer one ap-
proach to investigating causality in associations between
schizophrenia and SUDs. A form of instrumental variable
analysis, MR refers to the random assignment of an indi-
vidual's genotype at conception. If sets of genetic variants
can robustly predict an exposure of interest (e.g., drawn
from a well-powered GWAS), they can be used as uncon-
founded proxies of the exposure (i.e., instruments) and
tested with respect to a specific outcome, assuming that
possible pleiotropy is accounted for.
Two studies have used MR methods to investigate
causality in the association between cannabis use and
schizophrenia [7, 8]. Vaucher et al. reported that the top
ten loci from a GWAS of cannabis use were associated
with an increased risk of schizophrenia, when tobacco
exposure and pleiotropy were taken into account [7]. Gage
et al. found similar results and reported a modest effect
(odds ratio (OR) <1.07) of genetic liability to cannabis use
on the risk of schizophrenia [8]. However, they also re-
ported a stronger “causal” effect of genetic liability to
schizophrenia on cannabis use (OR = 1.10). This asym-
metry in the association might be attributable to multiple
factors. First, cannabis use may represent an imprecise
and relatively heterogeneous phenotype. For instance, one
of the largest GWAS of cannabis dependence symptoms
failed to find genome-wide evidence for pleiotropy with
schizophrenia [2]. Second, the reduced sample size of the
cannabis dependence GWAS with respect to the
schizophrenia GWAS (32,330 versus 150,064 individuals,
respectively [3, 4]) might have attenuated the predictive
utility of the cannabis instrument; that is, the directional
predictive power was asymmetrical. Third, the association
might reflect evidence for reverse causation (i.e., suggest-
ing that genetic liability to schizophrenia results in the
onset of the disorder, which further contributes to an
escalation of cannabis use). Alternatively, consistent withprior PRS studies [5], these limited-power MR analyses
may not have fully eliminated the role of a shared genetic
architecture underlying the comorbidity between cannabis
use (or other SUDs) and schizophrenia.
Gene–environment interplay
An alternative to both causation and pleiotropy is that
early-onset and heavy cannabis use might trigger an
underlying genetic liability to schizophrenia. Using PRSs
from the large Psychiatric Genomics Consortium schizo-
phrenia GWAS, a 2015 study found that an increasing
genetic liability to schizophrenia in males was associated
with decreasing cortical thickness, which represents a
possible endophenotype (i.e., a trait that should be herit-
able, should co-segregate with a psychiatric disorder yet
be present even when the disease is not, and should be
found in non-affected family members at a higher rate
than in the population), but only as a function of increas-
ing cannabis use during adolescence [9]. Despite the
appeal of such gene-by-environment models, the power to
detect interactions is reduced compared with the power of
GWAS to detect genetic associations, especially given the
small effect sizes attributable to individual loci or PRSs.
Future investigations
If schizophrenia and SUDs share genetic underpinnings,
then this finding strongly challenges the rigid diagnostic
boundaries that separate these psychiatric disorders and
might have clinical implications. However, genome-wide
meta-analyses of SUDs on the same scale as those of
schizophrenia are lacking. Similarly to their schizophrenia
counterpart, the newly established SUD Working Group
of the Psychiatric Genomics Consortium aims to analyze
the largest compilation of GWAS data for a variety of
SUDs [10]. We are highly confident that discoveries from
these collaborative groups will deliver the genetic instru-
ments necessary to investigate the mechanisms respon-
sible for dual diagnosis in schizophrenia with better power
than is attainable today. This expected genetic information
will provide unbiased evidence that will be useful when
addressing relevant public health issues, such as the con-
sequences of cannabis use in the general population.
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